Cardiovascular Consequences of Obstructive Sleep Apnea (OSA): Role of Endothelin and Preventive Effects of Bosentan.

Trial Profile

Cardiovascular Consequences of Obstructive Sleep Apnea (OSA): Role of Endothelin and Preventive Effects of Bosentan.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Bosentan (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms BOSAS
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Dec 2015 Primary endpoint has not been met. (24 hour mean diastolic blood pressure), as per an article published in the Respirology
    • 08 Dec 2015 Results published in the Respirology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top